ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PRTA / options
BLSM (42) CRMD (59) KMDA (46) ASMB (16) ⌘ Pro Terminal →

Prothena Corporation plc (PRTA) Options Positioning, Max Pain & Unusual Sweeps

$8.29 -2.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.24

Prothena Corporation plc (PRTA) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $434.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Prothena Corporation plc (NASDAQ: PRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $8.29 (-2.12% 1D, market cap $434.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRTA ranks #944 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRTA compare to BLSM and CRMD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRTA carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLSM (BlossomHill Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M) and CRMD (CorMedix Inc.) posts a C- grade (59/100 RQD, P/E 3.7x, ROIC 45.5%, cap $443.9M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRTA?
▼

Per PRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001559053), Prothena Corporation plc generated $9.7M in revenue (-92.8% YoY), -$244.1M in net income, and -$163.6M in free cash flow against $326.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.24 (-0.57%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510023
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (6)SEC (3)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15.8% Base Target
$12 Bull$7 Base$5 Bear
📬 FREE PRTA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRTA)Realized 20D OHLCV Swing Band: ±11%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY PRTA SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (30% of score)

FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (26% of score)

20D Institutional Volume Accumulation (±11% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$8.36+1.7% Next Q
Q2 (-2Q)
28
Grade E$8.50+3.6% Next Q
Q3 (-1Q)
26
Grade E$8.81-5.9% Next Q
Current
23
Grade E$8.29-11.1% Hist 90D α
Trajectory: E (31) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRTA currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.73) and Max Pain ($8.70) forces dealer call-delta covering toward $12.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 23%NO 77%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±11%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PRTA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PRTA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRTA)

  • ✓Walkthrough of PRTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PRTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.17%▼ DESCENDING CHANNEL
2026-11-03O $8.88H $8.88L $8.29C $8.29VOL 452.3K
RES: $9.21SUP: $7.71SMA50: $8.73SMA200: $9.23
$12.08$10.90$9.72$8.54$7.36RES $9.21SUP $7.71$8.292026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRTA Butterfly Map → + Track PRTA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -92.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PRTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRTA)

Health Care Rank #944 of 1015 ⚔️ BLSM vs PRTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRTA vs. BLSM, CRMD, KMDA, ASMB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Prothena Corporation plc (PRTA) ranks #944 by composite RQD confidence (23/100, grade E) and #464 by equity capitalization ($434.8M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while CRMD leads on capital efficiency and profitability with 45.5% ROIC and 88.5% gross margin. CRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with PRTA at 23/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRTA ACTIVE
Prothena Corporation plc
E 23/100 — — -35.0% -2.12% $434.8M Benchmark Subject
BLSM
BlossomHill Therapeutics Inc.
D- 42/100 — — — -9.67% $437.0M /blsm-vs-prta →
CRMD
CorMedix Inc.
C- 59/100 3.7x 88.5% 45.5% -5.36% $443.9M /crmd-vs-prta →
KMDA
Kamada Ltd.
D 46/100 — — — -4.42% $444.4M /kmda-vs-prta →
ASMB
Assembly Biosciences Inc.
E 16/100 — — -6.5% -3.08% $409.9M /asmb-vs-prta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001559053 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prothena Corporation plc (PRTA) reported GAAP revenue of $9.7M (-92.8% vs. FY2024 revenue of $135.2M , and -89.4% cumulative change since FY2023) , GAAP net income of -$244.1M, operating cash flow of -$163.6M, and free cash flow of -$163.6M (-9.0% YoY). On the balance sheet, PRTA closed FY2025 with $326.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $9.7M -$244.1M -$163.6M -$163.6M $326.8M —
FY2024 (FY) 2024-12-31 $135.2M -$122.3M -$150.1M -$150.1M $547.1M —
FY2023 (FY) 2023-12-31 $91.4M -$147.0M -$133.9M -$133.9M — —

3. PRTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Prothena Corporation plc (NASDAQ: PRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $8.29 (-2.12% 1D, market cap $434.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRTA ranks #944 in composite RQD confidence.

How does PRTA compare to BLSM and CRMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRTA carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLSM (BlossomHill Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M) and CRMD (CorMedix Inc.) posts a C- grade (59/100 RQD, P/E 3.7x, ROIC 45.5%, cap $443.9M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRTA?

Per PRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001559053), Prothena Corporation plc generated $9.7M in revenue (-92.8% YoY), -$244.1M in net income, and -$163.6M in free cash flow against $326.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRTA trading relative to its 50-day, 200-day, and 52-week technical levels?

PRTA last traded at $8.29 (-2.12% on volume of 462,524 shares), positioning the stock -5.04% below its 50-day simple moving average ($8.73) and -10.18% below its 200-day simple moving average ($9.23). Across its 52-week range of $7.73 to $11.80, PRTA sits at the 13.8% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($7.38 to $9.20).

Direct Sub-Reports: PRTA RQD Cockpit PRTA 12M Forecast PRTA Earnings & Move PRTA Dividends & DRIP PRTA Insiders & 13F PRTA Whale Options PRTA Profit Sankey PRTA News & Why
ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ SEC XBRL & RQD VERIFIED

PRTA — Prothena Corporation plc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Prothena Corporation plc (PRTA) earns a live Roarable RQD composite score of 23/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $8.29 (-2.12% 1D, market capitalization $434.8M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

.5B. Reported revenue was $9.7M in FY 2025, $135.2M in FY 2024, and $91.4M in FY 2023, indicating material year-to-year variation. — for further detail on how the company monetizes its activities.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Prothena Corporation plc (PRTA) reported $9.7M in annual revenue (up from $135.2M in FY2024, -92.8% YoY) and -$244.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($91.4M revenue, -$147.0M net income) through FY2025, PRTA scaled operating cash flow to -$163.6M and free cash flow to -$163.6M, backed by $326.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 23/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $7.73 – $11.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PRTA carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can PRTA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $9.7M and free cash flow of -$163.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PRTA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PRTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Prothena Corporation plc (PRTA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRTA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRTA Bull vs. Bear Conversation Board — What's Your Call at $8.29?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRTA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PRTA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $10.16 (+20.0%)
📌 Pinned Debate

Cash of $307.5M at FY 2025 provides a balance-sheet buffer while the stock trades near the low end of its $7.73 - $11.8 52-week range.

Long PRTA at $8.47 targeting $10.16. Cash of $307.5M at FY 2025 provides a balance-sheet buffer while the stock trades near the low end of its $7.73 - $11.8 52-week range.. Institutional whale score is 6/20 and the risk/reward vs. the $7.73 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 6/20 institutional whale-flow stock at $8.47 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $7.11 (-16.1%)
Spot @ $8.47

With ROIC at -35%, FCF yield at 0%, and an Altman Z of 0.2, the RQD rating flags forensic distress risk and recommends avoidance.

Sitting on the sidelines or leaning short PRTA above $8.47. With ROIC at -35%, FCF yield at 0%, and an Altman Z of 0.2, the RQD rating flags forensic distress risk and recommends avoidance.. Until Fundamental Cash Engine (5/20) and FCF yield (0.0%) inflect higher, upside is capped near $11.80.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%